The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systematic review

European Respiratory Journal

Volumn 16, Issue 2, 2000, Pages 253-262

  Stey, C ^a   Steurer, J ^a   Bachmann, S ^a   Medici, T C ^a   Tramer M R ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Bronchitis; Meta analysis; N acetylcysteine

Indexed keywords

ACETYLCYSTEINE; PLACEBO;

ARTICLE; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; GASTROINTESTINAL DISEASE; HUMAN; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; BRONCHITIS; CHRONIC DISEASE; EXPECTORANTS; HUMANS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 0033898870     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3003.2000.16b12.x     Document Type: Article

References (69)

1. Terminology, definitions and classification of chronic pulmonary emphysema and related conditions. A report of the conclusions of a Ciba Guest Symposium
2. Definition and classification of chronic bronchitis for clinical and epidemiological purposes
3. Clinical recognition of N-acetylcysteine in chronic bronchitis
4. Possible mechanisms behind the anti-inflammatory effects of N-acetylcysteine: Is metabolism essential?
5. Oxidative stress in chronic obstructive pulmonary disease
6. Management 1997 of chronic obstructive pulmonary disease
7. Optimal assessment and management of chronic obstructive pulmonary disease (COPD)
8. Guidelines for the management of chronic obstructive pulmonary disease
9. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease
10. Guidelines for the management of chronic obstructive pulmonary disease
11. The national mucolytic study. Results of a randomised, double blind, placebo controlled study of iodinated glycerol in chronic obstructive bronchitis
12. Assessing the quality of randomised clinical trials: Is blinding necessary?
13. Calculating confidence intervals for relative risk, odds ratios, and standardised ratios and rates
14. Beta blockade during and after myocardial infarction: An overview of the randomized trials
15. An assessment of clinically useful measures of the consequences of treatment
16. Using numerical results from systematic reviews in clinical practice
17. The number-needed-to-treat: A clinically useful measure of treatment effect
18. Studio clinico sull'efficacia terapeutica e la tollerabilita dell'acetlilisteina per via orale in un'unica somministratione al giorno nel trattamento delle broncopneumopatie
19. Efficacia terapeutica tollerabilita dell acetilcysteina per via vale in un unica somministrazione al giorno (fluimucil 600)
20. Valutazione clinica dell'effiacia e della tollerabilita della nuova formulazione farmaceutica bromessina granulare nei confront) dell'N-acetilcisteina granulare in piccoli patient) affetti da bronchite acute
21. Clinical effectiveness of and tolerance to cytiolone in the treatment of acute respiratory tract diseases. A controlled clinical study versus N-acetylcysteine
22. Valutazione delle equivalenza terapeutica di due diverse formulazioni orali di N-acetilcisteina
23. Sull' attivita di NA 872 (mucosolvan) nelle bronchopneumopatie croniche: Studio clinico controllato in confronto ad acetilcisteina (fluimucil)
24. Studio controllato sull'efficacia della 2 (alfa-tenoiiiltio)-propionilglicina e della n-acetilcisteina per via vale nella bronchopatia chronica ostruttiva
25. Study of the N-acetylcysteine (NAC) by oral or intravenous administration in chronic bronchitis
26. Clinical trial comparing 2 (alpha-thenoyltio) propionylglycine and acetylcysteine in chronic bronchitis
27. Un nuovo broncosecretoitico: Ambroxol (NA 872) - Studio CA-Aico controllato in confronto ad acetilcisteina (fluimucil)
28. A controlled, double blind clinical study of the effectiveness and tolerability of cytiolone in the treatment of chronic bronchitis in the elderly smoker
29. Wirksamkeit und Vertraglichkeit von N-Acetylcystein bei Patienten mit chronischer Bronchitis. Vergleich der Behandlungsschemata 3 x 200mg/d und 1 x 600mg/d
30. Studio comparativo degli effeti della 2-(alfa-tenoiltio)propioniglicina e delacetilcisteina nei bronchiti cronici
31. Mittelfristige Behandlung der chronischen Bronchitis mit Nacetylcystein. Ergebnisse einer polyzentrischen schweizerischen Studie
32. Acetylcysteine (Fabrol) in chronic bronchitis-a study in general practice
33. Irish general practice study of acetylcystelne (Fabrol) in chronic bronchitis
34. Acute indications for acetylcysteine: Etude multcentrique en double aveugle avec acetylcysteine vale vs placebo
35. Mukolytisk effekt af acetylcystein sammenlignet med Bromheksin og placebo nos patienter med kronisk bronchitis
36. Mucolytic treatment in chronic obstructive pulmonary disease. Double blind comparative clinical trial with N-acetylcysteine, bromhexine and placebo
37. Untersuchung uber die klinisch-therapeutische Wirkung von Acetylcystein bei der Behandlung von Patienten mit chronisch obstruktiver Bronchitis
38. Die mukolytische Behandlung bei chronischer Obstruktion der Luftwege: Klinischer Doppelblindvergleich mit N-Acetylcystein, Bromhexin und Placebo
39. Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: A balanced double-blind trial with placebo control
40. Safety and drug interactions of oral acetylcysteine related to utilization date
41. Trattamento prolungato non antibaterico della bronchite cronica: Risultati di una ricerca multcentrica con acetilcisteina vale
42. Steroid respons efter langtidsbehandling med oral N-acetylcystein nos patienter med Kronisk obstruktir bronchitis
43. Klinischer Doppelblindversuch mit Acetylcystein, S-(Carboxymcthyl)-L-cystein-Natrium und Placebo bei chronischer Bronchitis
44. Oral acetylcysteine treatment in exacerbation of chronic bronchitis in 49 patients
45. Short treatment of respiratory disorders with an oral mucolytic agent. Double blind study with acetylcysteine versus placebo
46. N-acetylcystein bei chronischobstruktiver Bronchitis. Wirkung der Langzeitbehandlung im Sauglings- und Kindesalter
47. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organized by the Swedish Society for Pulmonary Diseases
48. Confronto tra acetilcisteina e placebo nel trattamento a lungo termine della bronchite cronica
49. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction
50. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis
51. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis
52. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: A double-blind placebo controlled study
53. Langzeittherapie mit Acetylcystein Retard-Tabletten bei Patienten mit chronischer Bronchitis. Eine doppelblinde-placebokontrollierte Studie
54. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study
55. Oral Fabrol (oral N-acetylcysteine) in chronic bronchitis
56. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis
57. The intrabronchial microbial flora in chronic bronchitis patients: A target for N-acetylcysteine therapy?
58. Empirical evidence of bias
59. Language bias in randomized controlled trials published in English and German
60. Impact of covert duplicate publication on meta-analysis: A case study
61. Size is everything - The impact of event rate variation on clinical trials and meta-analysis
62. The importance of quality of primary studies in producing unbiased systematic reviews
63. Bacterial infection in chronic obstructive pulmonary disease
64. A long term follow up of respiratory symptoms and ventilatory function in a group of working men
65. The faith of the chronic bronchitic: A report of the ten year follow up in the Canadian Department of Veteran's Affairs coordinated study of chronic bronchitis
66. The natural history of chronic airflow obstruction
67. Variables associated with changes in spirometry in patients with obstructive lung diseaeses
68. Outcomes following acute exacerbation of severe chronic obstructive lung disease